Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27936768 | 0.84 | NR1H4 (0.54) | GPBAR1L3MBTL1NR1H4GABRA5NTRK1 | |
| SCHEMBL29384878 | 0.81 | NR1H4 (0.57) | NR1H4 | |
| SCHEMBL19202559 | 0.81 | NR1H4 (0.57) | NR1H4 | |
| SCHEMBL2929241 | 0.81 | GABRA5 (0.49) | GPBAR1L3MBTL1GABRA5MAPT | |
| SCHEMBL30395460 | 0.76 | GPBAR1 (0.63) | GPBAR1L3MBTL1NTRK1MAPT | |
| SCHEMBL12544227 | 0.76 | GPBAR1 (0.63) | GPBAR1L3MBTL1NTRK1MAPT | |
| SCHEMBL2962082 | 0.75 | GABRA5 (0.51) | GPBAR1GABRA5P2RX7MAPT | |
| SCHEMBL19033 | 0.75 | HSD17B10 (0.65) | GPBAR1L3MBTL1 | |
| SCHEMBL21752793 | 0.74 | GPBAR1 (0.49) | GPBAR1L3MBTL1NR1H4HSD11B1NTRK1 | |
| SCHEMBL21840049 | 0.74 | NR1H4 (0.56) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020040343-A1 | ISOXAZOLE DERIVATIVES AND PREPARATION PROCESS THEREOF | IL-YANG PHARM. CO., LTD. (KR) | 2020-02-27 | — | — | WO | disclosed |